Precision BioSciences Gets Clearance for Additional PBGENE-DMD Trial Dosing After Safety Review

Bitget2026/11/05 12:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Precision BioSciences can dose additional patients in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy following independent safety review.
Reported findings showed no safety concerns in the first patient through eight weeks, supporting further enrollment in Part 1.
Safety and efficacy updates from the trial are planned throughout 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050700BIZWIRE_USPR_____20261105_BW715224) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Precision BioSciences Gets Clearance for Additional PBGENE-DMD Trial Dosing After Safety Review

You may also like

Crypto prices